Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recent progress in the field of RNA therapeutics has highlighted the potential of using RNA-based strategies for the treatment of human cancer. Emerging technologies such as small interfering RNA (siRNA) to trigger RNA interference (RNAi) and catalytic RNA molecules, called ribozymes, are being developed to modulate expression of genes to either block tumourigenesis itself, inhibit tumour growth or prevent metastasis. Delivery of mRNA or vectors based on positive-strand RNA viruses such as alpha viruses, picornaviruses and flaviviruses have also found applications in the development of cancer vaccines and for apoptosis of tumour ce lls. These approaches should help overcome some of the drawbacks of viral vectors used in the majority (∼ 60%) of clinical trials for cancer gene therapy, including potential malignant transformation due to insertional mutagenesis with retroviral delivery and pre-existing immune responses to adenoviral proteins. In this review, the advantages and disadvantages of RNA-based therapeutic strategies and their potential use in cancer treatments will be compared.

Original publication

DOI

10.1517/13543776.13.5.627

Type

Journal article

Journal

Expert Opinion on Therapeutic Patents

Publication Date

01/05/2003

Volume

13

Pages

627 - 638